Form D · Biotechnology

AsclepiX Therapeutics, Inc.

Bethesda, MD · CIK 0001697751

Offering snapshot reported Apr 26, 2024 · SEC filing

Reported sold
$10M
Offering amount: $12.5M
Investors reported
9
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 19, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 26, 2024Initial$10,044,498No comparison9SEC filing
Jun 11, 2020Initial$10,000,000No comparison34SEC filing
Jun 17, 2019Amendment$7,735,500$3,858,500vs Oct 25, 201826SEC filing
Oct 25, 2018Initial$3,877,000No comparison15SEC filing
Feb 9, 2017Initial$175,000No comparison5SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-511712

Source: Form D, filed Apr 26, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Steven Altschuler Director
Steven Altschuler, Md Director
Ben Askew Director
Joshua Barer Director
Josh Barer Director
Robert Dempsey Executive
Chris Garabedian Director
Jordan Green Director
Niranjan Pandey Executive
Wendy Perrow Director, Executive
Aleksander Popel Executive
Aleksander S. Popel, Ph D Director
Amir Shojaei Executive
Kevin Slawin, Md Director, Executive
Sapna Srivastava Director
Jill Tierney Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
5237 River Road #334
Bethesda, MD, 20816